Madison-based Mithridion gets orphan drug designation for leading compound
Congratulations to Mithridion, a Madison drug development company headed by MadREP board member Trevor Twose, on receiving orphan drug designation for its leading compound, MCD-386CR.
Excerpted from the Wisconsin State Journal (May 9, 2010):
The drug is intended to treat progressive supranuclear palsy, or PSP, a degenerative brain disease that affects balance, walking, speech, cognition and eye movements.
Getting orphan drug status gives MCD-386CR seven years of market exclusivity as a treatment for PSP, if it eventually is approved by federal regulators, said Mithridion chief executive Trevor Twose.